George Kemble Acquires Shares of Sagimet Biosciences
George Kemble purchased 39,567 shares of Sagimet Biosciences on June 12, 2026.
Key Points
- George Kemble bought 39,567 shares of Sagimet Biosciences on June 12, 2026, as shares traded at $6.48.
- Sagimet Biosciences, trading on NasdaqGM, has a market cap of about $399.5 million and no meaningful P/E ratio due to negative earnings.
- Analysts maintain a positive outlook with multiple 'buy' ratings, including a high price target of $49.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
George Kemble recently purchased 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) on June 12, 2026. The shares were acquired as part of an insider transaction, with the stock trading at $6.48 at the time of the purchase.
Other Institutional Activity in Sagimet Biosciences
Vanguard Capital Management LLC significantly boosted its position in Sagimet Biosciences by adding 1,098,919 shares, bringing its total to 1,098,919 shares valued at approximately $5.74 million. Marshall Wace, LLP also increased its holdings by 185,807 shares, reaching a total of 966,253 shares worth about $5.04 million. Meanwhile, Affinity Asset Advisors, LLC reduced its stake by 280,225 shares, ending with 868,020 shares valued at $4.54 million.
Sagimet Biosciences Inc. Stock Down 38.7%
Shares of Sagimet Biosciences (NasdaqGM: SGMT) traded at $6.48. The company, with a market cap of approximately $399.5 million, operates in the biotechnology sector. It has no meaningful P/E ratio due to its negative earnings. The stock's 52-week range is between $4.50 and $11.41, with a 50-day moving average of $6.82 and a 200-day moving average of $6.56. Sagimet maintains a strong balance sheet with a current ratio of 20.34 and a quick ratio of 19.74.
Recent Earnings
Sagimet Biosciences is expected to report its next earnings on August 12, 2026. The company has been working on developing novel therapeutics, but it currently has negative earnings per share (EPS) of -$1.35 and a return on equity (ROE) of -36.04%.
Insider Buying and Selling at Sagimet Biosciences Inc.
On June 12, 2026, several insiders, including Beth Seidenberg, Paul Hoelscher, Elizabeth Grammer, Anne Phillips, and Jennifer Jarrett, each purchased 39,567 shares of Sagimet Biosciences. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On May 19, 2026, Citizens maintained a 'buy' rating for Sagimet Biosciences with a price target of $12.00. Canaccord Genuity, on May 4, 2026, also maintained a 'buy' rating with a higher target of $49.00. Guggenheim, on April 29, 2026, reiterated its 'buy' rating with a target of $25.00. The consensus among analysts is a 'buy' rating, with a mean price target of $26.20 based on 10 analyst opinions.
About Sagimet Biosciences
Sagimet Biosciences Inc., based in San Mateo, California, is a clinical-stage biopharmaceutical company focused on developing fatty acid synthase (FASN) inhibitors to treat diseases related to metabolic and fibrotic pathways. Their lead candidate, Denifanstat, is an oral pill designed for conditions like metabolic dysfunction-associated steatohepatitis, acne, and certain cancers. The company, led by CEO David A. Happel, has 16 employees.
Bottom Line
George Kemble's recent purchase of Sagimet Biosciences shares highlights ongoing interest in the company's potential. Investors closely watch insider trading for signals, though it's important to remember that 13F filings and insider transactions reflect past actions and may not indicate current positions. With a focus on novel therapeutics, Sagimet Biosciences remains a company of interest, especially with multiple 'buy' ratings from analysts.
Get Sagimet Biosciences Inc. alerts
New 13F filings, insider trades, and analyst moves on $SGMT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.